Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News

Pfizer advertises smoking cessation drug despite health warnings

Laura Eggertson
CMAJ February 07, 2012 184 (2) E127-E128; DOI: https://doi.org/10.1503/cmaj.109-4087
Laura Eggertson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Pharmaceutical giant Pfizer Canada is using a national advertising campaign to persuade Canadians who want to quit smoking to use its smoking cessation drug varenicline (Champix), despite a recent study linking it to serious cardiovascular events.

The firm is precluded from doing so in the United States, which has tougher advertising standards than Canada, and some experts argue that the Canadian campaign should be halted by either the government or the firm itself. Doing so, they say, would be in accord with principles that the firm’s US parent must abide by as a result of regulations that prohibit manufacturers from using “reminder ads” to advertise drugs that carry black box warnings.

Pfizer Canada rolled out its varenicline campaign, “in a punctual way,” in January 2011. The campaign, which includes billboards, print and digital advertising, is intended “to encourage an open dialogue between a patient and his/her physician,” says Andrea Gilpin, a spokesperson for Pfizer Canada.

It features “reminder ads,” a type of direct-to-consumer advertisement that assumes people are already familiar with the condition for which varenicline is prescribed. They do not describe how well the drug works or its potential risks.

The ads carry the tag line “I did it!” and highlight varenicline’s brand name and a website, while advising people to talk to their doctor or health care professional about the drug’s merit.

Pfizer has since continued to expand the forums in which it is using the ads, despite research that indicates people who take varenicline are more likely to experience an irregular heartbeat, heart attack or stroke than people who take a placebo (www.cmaj.ca/lookup/doi/10.1503/cmaj.110218).

The meta-analysis of data from 14 double-blind randomized clinical trials found that people taking varenicline had a 72% higher risk of adverse heart-related events than those on placebo. It prompted Health Canada to launch a safety review of the drug and issue a warning advising consumers of “the possibility of a slightly increased risk of heart-related side effects in patients who have cardiovascular disease.”

Figure

A meta-analysis of data from 14 double-blind randomized clinical trials found that people taking varenicline had a 72% higher risk of adverse heart-related events than those on placebo.

Image courtesy of © 2012 Thinkstock

Health Canada has not yet concluded its review.

Varenicline, meanwhile, already carries warnings, as a result of Health Canada advisories issued in 2008, 2009 and 2010, concerning potential serious neuropsychiatric adverse events such as depression, agitation, hostility, behaviour changes, suicidal ideation and suicide. The regulator alerted health care professionals to those potential adverse effects, using what is known as a “Dear Doctor” letter, while posting warnings directed at consumers on the agency’s website.

In the US, the Food and Drug Administration compelled varenicline manufacturers to use the agency’s most serious level of “black box” warning because of those neuropsychiatric adverse events.

“The rationale is that because companies are not required to state risk information in reminder ads, it’s a public safety concern that people are not getting the warnings about the serious risks that you get from a drug with a black box warning,” says Barbara Mintzes, a professor of epidemiology and an assistant professor in anesthesiology, pharmacology and therapeutics at the University of British Columbia in Vancouver.

The fact that Canada does not have the same advertising standards, and Health Canada has less than one full-time position devoted to regulating pharmaceutical promotion, should not absolve Pfizer from the responsibility to advertise products in a manner consistent with the ethical standards in the home nation of its parent, Mintzes argues. “Because we have a more lax approach to enforcement in Canada, it doesn’t mean that a corporation should be advertising in a way that, on safety grounds, it’s not allowed to advertise in its country of origin.”

Mintzes was “completely horrified” to see varenicline ads on a billboard near her Vancouver home because of the serious nature of the adverse events associated with the medication.

“One of my concerns is that often, when you have a safety concern about a medicine, it will affect sales volumes, and rightly so,” Mintzes says. “When people see this billboard and it’s just a claim of easy success in quitting smoking from using this product, it doesn’t give you any idea of how this compares to other alternatives that might be around to quit smoking.”

Advertising Standards Canada, which must clear such advertisements before they can be aired or published, has reviewed and approved the varenicline campaign, Gilpin writes in an email.

Health Canada has not received any complaints about the campaign, spokesperson Olivia Caron writes in an email.

In 2010, retail pharmacists dispensed $58.4 million worth of varenicline in Canada, down from $64.9 million in 2009, according to IMS Brogan, a health services consulting firm. The firm has not yet analyzed 2011 sales figures.

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 184 (2)
CMAJ
Vol. 184, Issue 2
7 Feb 2012
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Pfizer advertises smoking cessation drug despite health warnings
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Pfizer advertises smoking cessation drug despite health warnings
Laura Eggertson
CMAJ Feb 2012, 184 (2) E127-E128; DOI: 10.1503/cmaj.109-4087

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Pfizer advertises smoking cessation drug despite health warnings
Laura Eggertson
CMAJ Feb 2012, 184 (2) E127-E128; DOI: 10.1503/cmaj.109-4087
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • What to know about Omicron XBB.1.5
  • Could a flu shot push help curb pediatric hospitalizations?
  • Stalemate: What’s holding up a new health accord?
Show more News

Similar Articles

Collections

  • Topics
    • Drug regulation
    • Tobacco control & smoking

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire